JAK2 and cancer: Across 61 non-cancer screening samples, two likely pathogenic variants, JAK2 V617F and TP53 M246I, were detected at 0.81% and 0.40% VAF respectively, demonstrating a per-base specificity of ≥99.9999%, giving a false positive variant rate of ≤0.0001% (1 in 1,000,000 bp).